Target intelligence / Profile preview

Apolipoprotein C-III (APOC3)

Target: APOC3
Molecular classification: Apolipoprotein

Overview

Apolipoprotein C-III is a central regulator of human triglyceride metabolism. It inhibits lipoprotein lipase and hepatic lipase activity, delays clearance of TG-rich particles from plasma, and promotes VLDL assembly/secretion in hepatocytes. Elevated apoC-III is associated with increased triglycerides, dyslipidemia, inflammation, atherosclerosis, and higher cardiovascular disease risk. Conversely, genetic or pharmacologic reduction lowers these risks significantly.

Mechanism of action

Inhibition of APOC3 expression

Biological functions

Lipid metabolismRegulation of plasma triglyceridesVLDL assembly/secretion

Disease associations

HypertriglyceridemiaAtherosclerosisCardiovascular disease

Interacting drugs

Antisense oligonucleotides targeting APOC3

Biomarkers

Plasma triglyceridesAPOC3 levels

Beyond the preview

Go deeper on Apolipoprotein C-III (APOC3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apolipoprotein C-III (APOC3).

Explore the full profile